Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense®
IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablation
CAESAREA, Israel, April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation at the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium which took place April 24-27, 2025 in Colorado Springs, Colorado.
IceCure Medical logo
IceCure was a sponsor of the SBI Breast Cryoablation courses where two classes were conducted for hands-on training with ProSense® on April 24 and 26. The sold-out courses, led by the SBI, are a testimony to the growing number of radiologists who are exploring integrating ProSense® into their clinics, with an increasing number of medical societies are adopting cryoablation into their curriculum.
At its booth, IceCure hosted a VIP Exhibitor Hour with Dr. Robert Ward, a ProSense® user. Dr. Ward is Assistant Professor of Diagnostic Imaging at the Warren Alpert Medical School of Brown University, Program Director for the Breast Imaging Fellowship, Associate Chief of Diagnostic Imaging at Women & Infants Hospital, and specializes in women's imaging and breast tumor cryoablation. Participants had the opportunity to learn about the rationale and techniques behind breast cryoablation and discuss the growing clinical data. Guest speaker Dr. Ward has made significant contributions to the growing clinical data for breast cancer cryoablation, including a publication featuring ProSense®, 'Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials' in the American Journal of Roentgenology.
"We believe that IceCure's mission is very well aligned with the SBI's, which is focused on early detection and early treatment to minimize the impact of breast cancer," stated Eyal Shamir, IceCure's Chief Executive Officer. "Once diagnosed by radiologists, ProSense® can quickly and minimally invasively destroy tumors before they destroy lives. We were pleased to get ProSense® in front of thousands of SBI society physicians in the U.S., as we look ahead to potential regulatory clearance for breast cancer in the U.S."
About SBI The Society of Breast Imaging (SBI) is an organization of over 4,000 radiologists, medical physicists, and other scientists and technologists who are expert and authoritative breast imagers working in supportive practice environments to advance the highest quality of breast care via early detection, diagnosis, and treatment. Its members support the SBI in championing breast imaging that is compassionate, evidence-based, and which saves lives and minimizes the impact of breast cancer.
About ProSense® The ProSense® Cryoablation System is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that IceCure's mission is very well aligned with the SBI's and the Company's potential regulatory clearance for breast cancer in the U.S. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
